11/3
08:39 am
inmb
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) [Yahoo! Finance]
Low
Report
INmune Bio Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) [Yahoo! Finance]
10/31
04:05 pm
inmb
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
Medium
Report
INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update
10/28
08:00 am
inmb
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
Medium
Report
INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB
10/24
03:08 pm
inmb
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination [Yahoo! Finance]
Low
Report
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination [Yahoo! Finance]
10/24
03:03 pm
inmb
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
Medium
Report
INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination
10/24
09:30 am
inmb
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
Medium
Report
INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
10/24
08:09 am
inmb
Insider Stock Buying Reaches US$951.2k On INmune Bio [Yahoo! Finance]
Low
Report
Insider Stock Buying Reaches US$951.2k On INmune Bio [Yahoo! Finance]
10/21
08:07 am
inmb
INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $20.00 price target on the stock.
Low
Report
INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Alliance Global Partners. They set a "buy" rating and a $20.00 price target on the stock.
10/11
08:30 am
inmb
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
Medium
Report
INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit
9/30
08:00 am
inmb
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
Low
Report
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
9/27
07:41 am
inmb
INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Raymond James. They set an "outperform" rating and a $18.00 price target on the stock.
Low
Report
INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Raymond James. They set an "outperform" rating and a $18.00 price target on the stock.
9/26
08:00 am
inmb
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
Low
Report
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
9/17
08:30 am
inmb
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
Low
Report
INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints
9/13
08:30 am
inmb
INmune Bio Announces $13.0 Million Registered Direct Offering
High
Report
INmune Bio Announces $13.0 Million Registered Direct Offering
9/13
08:06 am
inmb
INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions [Yahoo! Finance]
High
Report
INmune Bio, Inc.'s (NASDAQ:INMB) top owners are individual investors with 44% stake, while 23% is held by institutions [Yahoo! Finance]
9/3
09:00 am
inmb
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
Medium
Report
INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference
8/22
08:10 am
inmb
INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $22.00 price target on the stock.
Medium
Report
INmune Bio, Inc. (NASDAQ: INMB) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $22.00 price target on the stock.